NCT03444272 is a Phase 3 clinical trial of Sofosbuvir and Daklatasuvir in Hepatitis C, sponsored by Sherief Abd-Elsalam.

Who is sponsoring NCT03444272?

NCT03444272 is sponsored by Sherief Abd-Elsalam.

What drugs are being tested in NCT03444272?

Interventions in NCT03444272: Sofosbuvir and Daklatasuvir.

What condition does NCT03444272 study?

NCT03444272 studies Hepatitis C.

Is NCT03444272 still recruiting?

NCT03444272 is currently status unknown. Last updated 20 October 2020.

Last reviewed 2020-10-20 · How we verify

NCT03444272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Direct-acting Antiviral Drugs on Erectile Function Among Hepatitis c Patients

Status unknown Phase 3 Last updated 20 October 2020

What this trial tests

Phase 3 trial testing Sofosbuvir and Daklatasuvir in Hepatitis C in 105 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	Sherief Abd-Elsalam
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	105
Start date	1 January 2018
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across Egypt

Drugs / interventions tested

Sofosbuvir and Daklatasuvir — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Sherief Abd-Elsalam — full company profile →

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of patients with improved erectile functions
Time frame: 6 months
Number of patients with improved erectile functions

Sponsor's own description

Effect of direct-acting antiviral drugs on erectile function

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Sherief Abd-Elsalam trials

Trials by the same sponsor.

NCT05291455 — Lacosamide in Neonatal Status Epilepticus · Phase 3 · unknown
NCT04766177 — Role of Bumetanide in Treatment of Autism · Phase 3 · recruiting
NCT04499755 — Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics · Phase 3 · recruiting
NCT04499885 — Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning · NA · recruiting
NCT04216199 — Role of Point of Care Ultrasound in Endotracheal Tube Placement · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03444272 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sherief Abd-Elsalam
Last refreshed: 20 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03444272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing